IV NAD Therapy: What the Research Shows

The short version

IV NAD therapy means infusing NAD+ (the cell's energy-handling helper molecule) straight into a vein, usually at a wellness clinic. It is not FDA-approved — it is a compounded therapy, meaning mixed to order rather than manufactured as an approved drug. Two facts dominate the research: infused NAD+ is cleared from the blood within about two hours, and a compounded NAD+ injection was recalled for contamination. The controlled evidence is the thinnest of any route. This page reports what the studies and recalls say, and recommends nothing.

Status: unapproved, compounded, and quality-flagged

IV NAD therapy is an unapproved compounded wellness therapy. NAD+ delivered intravenously is not an FDA-approved treatment for any condition; it is prepared by compounding rather than manufactured under approved-drug controls. That distinction carries real risk: a compounded injectable NAD+ product was subject to an FDA Class I recall — the most serious recall category, reserved for products that could cause serious injury or death — for elevated bacterial endotoxin contamination [CAUTION]. Compounded injectables also vary in purity, and reconstituted NAD+ must be kept cold and protected from light to remain stable. None of this describes an approved therapy; it describes a marketed one with documented quality concerns.

What is an NAD injection?

An NAD injection or IV infusion delivers NAD+ directly into the bloodstream as a compounded wellness therapy. It is not FDA-approved; controlled evidence is limited, infused NAD+ is rapidly cleared from plasma ^[12], and a compounded NAD+ injection has been recalled for endotoxin contamination. It is distinct from oral precursors, which the controlled trials actually support ^[3][4].

Does NAD IV actually work?

IV NAD+ has minimal controlled evidence. Pharmacokinetic work shows infused NAD+ is extensively metabolized extracellularly and rapidly cleared from plasma — near-complete removal within roughly two hours — so the mechanism of any sustained benefit is unclear ^[12]. Most clinical reports are pilot or retrospective ^[8]. Marketed claims consistently outrun the published data.

The pharmacokinetic problem: infused NAD+ clears fast

The central scientific difficulty for IV NAD therapy is that the molecule does not persist. A pilot pharmacokinetic study found infused NAD+ was removed from plasma almost completely within roughly the first two hours ^[12], consistent with in-vitro work showing extracellular NAD is degraded by surface ecto-enzymes into nicotinamide, NMN and purine metabolites — with adenosine, not NAD+ itself, the principal product taken up by cells ^[12]. In other words, much of an NAD+ infusion is broken down outside the cell before it can act as NAD+. That undercuts the simple "refill your NAD+" marketing narrative and is why the route's mechanism remains contested even where symptom reports are positive.

The addiction studies: the strongest IV signal, still preliminary

The most-cited IV NAD+ evidence is in substance-use disorder. In a series of 50 treatment-resistant patients, IV NAD+ infusions with enkephalinase inhibition were associated with significant reductions in craving (p = 1.06 × 10⁻⁹), anxiety and depression, with 100% urine negativity for illicit substances in a 40-patient subset midway through treatment ^[13]. A narrative review traces IV NAD+ for addiction to a 1961 series of 104+ patients dosed at 500-1000 mg daily, reporting withdrawal-symptom relief, and notes a contemporary 750 mg IV protocol with no adverse effects at an appropriate infusion rate — while explicitly stating IV NAD+ remains FDA-unapproved and calling for rigorous RCTs ^[8]. This is the route's best case, and its authors still classify it as unproven [GAP].

Is an NAD+ shot worth it?

The controlled evidence for IV/injectable NAD+ is the weakest of any route; most data are pilot or retrospective ^[8]. A narrative review documents historical and contemporary addiction protocols, but the authors note IV NAD+ remains unapproved and call for rigorous randomized trials ^[8]. The oral-precursor trials ^[3][4] carry far stronger evidence. This is a research summary, not a purchasing or treatment recommendation.

When is NAD+ injected in the protocols studied?

Published IV NAD+ work used multi-day infusion protocols — for example several consecutive daily infusions in addiction case series and reviews, with historical regimens running 500-1000 mg daily for about four days then maintenance dosing ^[8]. No trial establishes an optimal timing for general use; these are descriptions of research protocols, not dosing instructions.

How to read marketed IV NAD+ claims

IV NAD+ is promoted for energy, focus, recovery, anti-aging and addiction, often with confident before-and-after language. Set those claims against the record on this page. The controlled human evidence is minimal and mostly pilot or retrospective ^[8]. The molecule clears the bloodstream within roughly two hours and is largely degraded outside cells before uptake, so the simple "refill your cells with NAD+" story is not what the pharmacokinetics show ^[12]. The product is compounded, not FDA-approved, and has a documented Class I endotoxin recall in its history [CAUTION].

The contrast with oral precursors is the useful anchor: NR and NMN have randomized, placebo-controlled trials showing dose-dependent, sustained blood-NAD+ elevation with good tolerability ^[3][4]. IV NAD+ has none of that caliber of evidence for general wellness use. A reader can hold both facts at once — the route is real and the symptom reports in addiction are interesting ^[13] — while recognizing that the marketing outruns the data. This is a research summary; it recommends no product, route, or provider.